



Nanospectra

Biosciences, INC.

COMPANY OVERVIEW:

Nanospectra is commercializing a particle-based therapy for the precise thermal destruction of solid tumors. By allowing the systemically delivered particles to determine the zones of ablation (rather than the placement of an energy source), AuroLase™ Therapy can thermally ablate irregularly shaped tumors or inoperable tumors while minimizing damage to healthy adjacent tissue and preserving nearby critical structures. The company was founded on intellectual property from Rice University and collaborative research with scientists at MD Anderson Cancer Center.

COMPANY FACTS:

- Business Focus: Medical Technology; Cancer
- Acting COO: Glenn Goodrich
- Headquarters: 8285 El Rio, Suite 150 Houston, Texas, USA, 77054 713-842-2720
- Investor/Media Contact: GGoodrich@Nanospectra.com
- Founded: 2002
- Structure: Private; Angel Investors and Venture Capital
- 2011 income: \$1.1 million (grants and sales)
- Employees: 5-10
- Website: www.Nanospectra.com

COMPANY MILESTONES:

- 2002: Commenced operations; license from Rice University
- 2003: Successful demonstration of in vivo efficacy in animals
- 2004: Received Advanced Technology Program award of \$2 million; advanced development of manufacturing
- 2006: Received Texas Emerging Technology Fund award of \$1.25 million; completed cGMP manufacturing facility
- 2007: Completed animal and laboratory toxicity/safety tests
- 2008: Received IDE and initiated human clinical trial study for use of AuroLase™ Therapy for refractory/recurrent head and neck cancer
- 2010: Completed eight subjects in the head and neck clinical trial
- 2011: Initiated a pilot study of AuroLase™ Therapy for primary prostate cancer (Mexico)
- 2012: Treated final subject in prostate cancer pilot study (Mexico), trial completes Q1 2013
- 2012: Received IDE and initiated human clinical trial study for use of AuroLase™ Therapy for primary and/or metastatic lung tumors